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ABSTRACT 
 
Chronic Myeloid Leukemia patients that fail Tyrosine Kinase Inhibitors (TKIs) often present 
mutations in the BCR-ABL catalytic domain. We noticed a lack of substitutions involving four 
amino acids (E286, M318, I360 and D381) that form hydrogen bonds with Ponatinib. We 
therefore introduced mutations in each of these residues either preserving or altering their 
physico-chemical properties. We found that E286, M318, I360 and D381 are dispensable for 
ABL and BCR-ABL protein stability but are critical to preserve catalytic activity. Indeed, only a 
“conservative” I360T substitution retained kinase proficiency and transforming potential. 
Molecular Dynamics simulations of BCR-ABLI360T revealed differences in both helix-alphaC 
dynamics and protein correlated motions consistent with a modified ATP binding pocket. 
Nevertheless, this mutant remained sensitive to Ponatinib, Imatinib and Dasatinib. These 
results suggest that changes in the four BCR-ABL residues described here would be selected 
against by a lack of kinase activity or by maintained responsiveness to TKIs. Interestingly, 
amino acids equivalent to those identified in BCR-ABL are conserved in 51% of human 
tyrosine kinases. Hence, these residues may represent an appealing target for the design of 
pharmacological compounds that would inhibit additional oncogenic tyrosine kinases while 
avoiding the emergence of resistance due to point mutations 
 
Ponatinib, Imatinib and Dasatinib inhibit BCR-ABLI360T kinase activity suppressing its transforming potential 
 
 
Key Words: CML, TKIs, Mutations, Resistance, Molecular Dynamics 
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INTRODUCTION 
 
Chronic Myeloid Leukemia (CML) has historically represented one of the few “paradigm diseases” in the field 
of cancer research (1-3). Indeed, CML has been one of the first malignancies associated with a known 
cytogenetic alteration (i.e. the Philadelphia chromosome) and a specific molecular hallmark (i.e. the BCR-ABL 
oncoprotein) (4, 5). Furthermore, specific BCR-ABL characteristics (e.g. constitutive tyrosine kinase activity, 
exclusive cytoplasmic localization) have been ingeniously targeted to devise innovative therapeutic strategies 
that have ushered the era of tailored cancer treatment (6, 7). 
 
Suppression of BCR-ABL catalytic activity by the Tyrosine Kinase Inhibitor (TKI) Imatinib Mesylate (IM) has 
dramatically improved the natural history of CML (5). Despite the unparalleled results achieved by this drug, 
approximately 30% of CML patients fail IM (3). To address this critical issue, second and third generation TKIs 
(e.g. Dasatinib and Ponatinib) have been generated and tested on IM-resistant individuals, enjoying early 
clinical success (8, 9). However, more mature data suggest that up to 50% of patients receiving either Dasatinib 
(DAS) or Ponatinib (PON) will not obtain long-term benefit from these drugs and will progress to the advanced 
phases of the disease (10, 11). 
 
Multiple mechanisms have been proposed to explain TKIs failure. While this phenomenon can recognize 
different causes, point mutations in the BCR-ABL kinase domain (KD) are one of the most common reasons 
underlying TKI resistance (12-15). Substitution of Threonine 315 with an Isoleucine (T315I) represents the 
most problematic BCR-ABL mutation as alterations of this gatekeeper residue preserve the oncoprotein’s 
kinase activity while inducing resistance to first and second generation TKIs (16, 17). Furthermore, recent 
evidence suggests that the T315I substitution is associated with inferior overall and failure-free survival (18). 
 
Since the mechanisms allowing different BCR-ABL mutants to avoid catalytic inhibition by first, second and 
third generation inhibitors are still partially unresolved, there is a clear need for a structural characterization of 
the interactions occurring between the BCR-ABL KD and different TKIs. Experimental measures and 
quantification of the delicate balance of different physico-chemical components are very difficult to obtain and 
a complete overview of the molecular determinants in the inhibitors binding modes is challenging for this class 
of flexible proteins. Molecular Dynamics (MD) investigations represent an ideal tool to extract energetic and 
dynamical features in binding processes and conformational equilibria. In this respect, computational studies 
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addressing BCR-ABL binding mechanisms can be grouped in three types of approaches: i) studies addressing 
the BCR-ABL KD alone, aimed at characterizing the equilibrium between the active and inactive conformations 
(19-21); ii) studies addressing binding to various inhibitors (22-24); and iii) studies evaluating the impact of 
mutations on BCR-ABL kinase activity (25-30). However, a comparative investigation of the binding modes 
and dynamics characterizing the interactions between the BCR-ABL kinase and different TKIs is still lacking. 
 
By analyzing all reported BCR-ABL point mutations associated with TKI resistance (12-15), we noticed a lack 
of amino acidic substitutions involving four residues (E286, M318, I360 and D381) that are known to generate 
hydrogen bond interactions with PON (31) (Fig. 1A). The same residues (with the addition of T315) also 
generate hydrogen bonds with IM (32) (Fig. 1B), while T315 and M318 are the only amino acids forming 
hydrogen bonds with DAS (33) (Fig. 1C). We therefore employed a combined experimental and computational 
approach to investigate the effects of different mutations on these amino acids. Our results shed light on the 
molecular details underlying the essential role of E286, M318, I360 and D381 in preserving BCR-ABL kinase 
activity and oncogenic potential. We also outline some of the fingerprints of the inhibition mechanisms of PON, 
IM and DAS, offering a rationale for PON-dependent inhibition of all described BCR-ABL point mutations, 
including T315I. Since we report that 51% of human tyrosine kinases retain residues equivalent to those 
forming hydrogen bonds between BCR-ABL and PON, our results may aid the design of inhibitory compounds 
targeting additional kinases involved in the development of other malignancies. 
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MATERIALS AND METHODS 
 
Mutagenesis and Constructs 
The BCR-ABL sequence, cloned in the expression vector pcDNA3.1 (Life Technologies, Grand Island, NY, 
USA), was mutagenized using the QuikChange II XL Site-Direct Mutagenesis Kit (Agilent Technologies, Santa 
Clara, CA, USA). Incorporation of each mutation was verified by direct sequencing. Every BCR-ABL construct 
was then amplified by PCR using the indicated forward (FLAG-tag underlined) 5’-
GACTAGTGCCACCATGGATTACAAGGATGACGACGATAAGATGGTGGACCCGGTGGGC-3’ and 
reverse 5’-CGACGCGTCTACCTCTGCACTATGTCACT-3’ primers and cloned in the SpeI and MluI unique 
sites of the pLEX lentiviral vector (Open Biosystems, Lafayette, CO, USA). To generate ABL constructs 
corresponding to the reported native and mutated BCR-ABL, we amplified the first 425 base pairs of the ABL1A 
coding sequence from HL-60 immortalized cells (DSMZ, Braunschweig, Germany) and substituted this 
amplimer to the BCR sequences located upstream of the ABL breakpoint. PCR reactions were carried out with 
the indicated forward (HA-tag underlined) 5’-
CTAGCTAGCGGATCCATGTACCCATACGATGTTCCAGATTACGCTATGTTGGAGATCTGCCTGAAG
C-3’ and reverse 5’-CTCAGCAGATACTCAGCGGCAT-3’ primers. The ensuing PCR product was initially 
cloned in the pcDNA 3.1 vector using the NheI (on the forward primer) and KpnI (in the ABL1A sequence) 
restriction sites. Each ABL construct was subsequently subcloned in the BamHI and NotI unique sites of the 
pLEX vector. 
 
Cell Culture, Transfection and Lentiviral Transduction 
Ba/F3 cells (DSMZ) were maintained in RPMI-1640 medium (Sigma-Aldrich, St. Louis, MO, USA) 
supplemented with 4 mM L-glutamine, 50 Units/mL penicillin, 50 µg/mL streptomycin (all from Sigma-
Aldrich), 10% fetal bovine serum (FBS) (Lonza, Basel, Switzerland) and 10% WEHI-3B conditional medium, 
as a source of Interleukin 3 (IL-3). WEHI-3B cells (DSMZ) were grown in Iscove’s Modified Dulbecco’s 
Medium (Sigma-Aldrich), supplemented with 2 mM L-glutamine, 50 Units/mL penicillin, 50 µg/mL 
streptomycin, 10% FBS and 25 µM 2-mercaptoethanol (Sigma-Aldrich). All cells were grown at 37°C in 5% 
CO2. For the production of the lentiviral supernatant, transfer vectors (empty vector, native and mutant ABL and 
BCR-ABL constructs) were co-transfected with the packaging plasmids in the HEK293T cell line, using the 
calcium phosphate transfection method (Trans-Lentiviral™ ORF Packaging Kit, Open Biosystems, catalog 
number: TLP4617). Viral supernatants were harvested 48 hours after transfection. Ba/F3 cells were then 
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transduced by a double round of spin-infection (90 minutes, 1200 x g at 32°C) in the presence of 1 mL of viral 
supernatant and 8 µg/mL polybrene (Sigma-Aldrich). Transduced cells were finally selected with 3 µg/mL 
puromycin (Sigma-Aldrich) for 72 hours. 
 
Proliferation Assays and Drug Treatments 
1 x 104 Ba/F3 cells transduced with empty vector, wild-type or mutant ABL or BCR-ABL constructs were plated 
in quadruplicates in a 96-well plate in the absence of IL-3. Cell proliferation was assessed after 24, 48 and 72 
hours using the ATPlite luminescence kit (Perkin-Elmer, Waltham, MA, USA) following the manufacturer’s 
instructions. To calculate the IC50 values for cellular proliferation of different TKIs, Ba/F3 cells transduced with 
empty vector, wild-type, T315I and I360T BCR-ABL were plated in triplicate and incubated for 24 hours with 
logarithmic dilutions of PON (Santa Cruz Biotechnology, Santa Cruz, CA, USA), IM (a gift from Novartis, 
Basel, Switzerland) and DAS (a gift from Bristol-Myers Squibb, Princeton, NJ, USA). IL-3 was maintained in 
the culture media of Ba/F3 cells transduced with the empty vector. Proliferation was measured using 
CellTiter96 Aqueous One Solution Reagent (Promega, Madison, WI, USA). IC50 values were calculated using 
the logistic nonlinear regression included in GraphPad Prism 5.0 (GraphPad Software Inc.) and are reported as 
the mean of three independent experiments. For evaluation of total tyrosine kinase activity by immunoblots, 
Ba/F3 cells transduced with BCR-ABLWT, BCR-ABLT315I or BCR-ABLI360T were treated for 24 hours with the 
IC50 concentrations determined for PON, IM and DAS. 
 
Immunoblots 
Ba/F3 cells expressing empty vector, native or mutant ABL or BCR-ABL proteins were starved of IL-3 for 4 
hours (or 24 hours when exposed to TKIs) before centrifugation and suspension in isotonic buffer containing 
100 mM NaCl, 25 mM Trizma Base pH 8.5, 2 mM PMSF and 1x protease inhibitor cocktail (Roche, 
Mannheim, Germany). Proteins were extracted by sonication and analyzed by SDS-PAGE loading 60 µg of cell 
lysate per lane. Blots were probed using anti-HA (Covance, Princeton, NJ, USA), anti-FLAG (Sigma-Aldrich), 
anti-phosphotyrosine (clone 4G10 by Millipore, Billerica, MA, USA) and anti-Actin (Sigma-Aldrich) 
monoclonal antibodies. 
 
Purification of BCR-ABL proteins and in vitro kinase assays 
BCR-ABL constructs cloned in the pLEX vector were modified to include six histidine codons at the N-terminal 
to allow protein purification. As a negative control, we generated a kinase inactive (KI) BCR-ABL mutant 
carrying the K271H substitution (ABL1A numbering) in the ABL kinase domain as previously described (34). 
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The Ni2+-nitrilotriacetic acid (Ni-NTA) Purification System (Life Technologies) was employed for protein 
purification under native conditions. BCR-ABL constructs were expressed by transient transfection in HEK293T 
cells using the calcium phosphate method. After 48 hours, 1 x 107 cells were lysed in 8 mL of 1X Native 
Binding Buffer, supplemented with 0.5% Triton X-100, 5% glycerol, 0.1 mM PMSF and 2 µg/mL Aprotinin. 
Lysates were loaded onto pre-equilibrated Ni-NTA agarose columns and purified following the manufacturer’s 
protocol. Proteins were then eluted in 6 mL of Native Elution Buffer and concentrated up to 100-fold by Spin-X 
UF Concentrators (Corning, Corning, NY, USA). Concentration of BCR-ABL proteins was determined by SDS 
PAGE analysis and Coomassie Blue staining using purified bovine serum albumin (BSA, Sigma-Aldrich) as a 
comparative standard, with quantification carried out by densitometry using the ImageJ software. 
Detection of kinase activity was performed using the Kinase Glo luminescence assay (Promega) with an ABL 
peptide substrate (Abltide, SignalChem, Richmond, Canada). Assays were carried out in triplicates, at room 
temperature, for 1 hour, using 12 nM enzyme, 50 µM ATP and peptide concentrations of 1.56, 3.12, 6.25, 12.5, 
25, 50, 100 and 200 µM. Luminescence values were measured using a Victor Wallac microplate reader (Perkin-
Elmer) and normalized for background ATP to ADP conversion by omitting peptide substrate from the kinase 
reaction. Non linear regression fits (GraphPad Prism 5.0) were used to determine Vmax, Km and Michaelis-
Menten kinetics by plotting velocity as a function of peptide concentration for each mutant. Velocity values are 
reported as signal to background ratio. Kcat was obtained from the equation kcat = Vmax/[enzyme]. 
 
Structures Preparation, Molecular Dynamics Simulations and Energetic Analysis 
Molecular Dynamics (MD) simulations were performed on the human wild-type ABL KD, and the T315I, 
I360T and I360R mutants. For the ABLWT, ABLT315I and ABLI360T systems simulations were also performed in 
complex with PON, IM and DAS. Starting structures for the mutants were derived by in silico mutagenesis with 
MODELLER v9.8 (35). The following structures were downloaded from the Protein Data Bank (36): inactive 
or “closed” conformation with PON (PDB: 3OXZ (31)), inactive conformation with IM (PDB: 2HYY (37)) and 
active or “open” conformation with DAS (PDB: 2GQG (33)). Unbound forms were generated by manual 
removal of the inhibitors. Missing residues were rebuilt with MODELLER v9.8. The GROMACS 4.0 program 
(38) was used to prepare the initial system coordinates, run the MD simulations, and analyze the resulting 
trajectories. Simulations were performed using the ffamber99sb (39) porting of the AMBER parm99 force field 
(40), the TIP3P model for water (41) and the General AMBER Force Field (GAFF) (42) with the AM1-BCC 
charges (43) for the inhibitors. The systems were minimized and then gradually heated to 300 K with potential 
restraints on the solute performing several steps of equilibration (44). After equilibration, the resulting 
structures were used as a starting point for production of 50 ns MD simulations. Secondary structure analysis 
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was performed with DSSP (45). The extent of correlated motions was estimated from the correlation matrices 
on Cα positions and represented as correlation webs (46). The energetic analysis was performed with the 
Molecular Operating Environment 2012.10 (MOE). The Pose Rescoring method of the Dock module was used 
to calculate the free energy of binding for each simulated system in complex with the three TKIs. 
Representative structures were extracted by cluster analysis (47) from each MD trajectory and validated with 
the MOE Structure Preparation module. Average values calculated over the representative structures of the 
three largest clusters were reported. The GBVI/WSA dG scoring function with the Amber12EHT force field 
was used (48). In silico mutagenesis scanning was performed with the Residue Scan method of the Protein 
Design module. The representative structure of the largest cluster in the MD trajectory of ABLWT was used. 
Sequence-based predictions of the effect of each mutation were performed with the web servers PROVEAN 
(49), SIFT (50) and polyphen-2 (51). Images were generated with VMD 1.8.5 (52) and PyMOL 1.2 
(Schrodinger Inc). 
 
Multiple sequence alignment of Tyrosine Kinase proteins 
Kinase domain sequences were downloaded from the website http://kinase.com. The human tyrosine kinase 
subset (90 sequences) was extracted and aligned using T-Coffee (53). 
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RESULTS 
 
PON binds to the inactive conformation of the BCR-ABL catalytic pocket by generating hydrogen bonds with 
four amino acids: E286, M318, I360 and D381 (Fig. 1A) (31). Interestingly, these residues do not undergo 
substitutions in patients failing TKI therapy (12-15). We therefore decided to generate point mutations in these 
sites and investigate their effect on the expression and kinase activity of both ABL and BCR-ABL. To this end, 
we engineered eight ABL and eight BCR-ABL constructs displaying two alternative substitutions in E286, 
M318, I360 and D381. The inserted mutations were deemed conservative if they preserved the 
physical/chemical properties of the amino acid found in the wild-type sequence, or non-conservative if they 
altered these characteristics (Table 1). ABL and BCR-ABL constructs displaying the wild-type sequence or 
bearing the T315I substitution were used as controls. 
 
E286, M318, I360 and D381 are dispensable for ABL and BCR-ABL protein stability but are critical to 
preserve BCR-ABL catalytic activity 
As point mutations in E286, M318, I360 and D381 have never been reported in CML patients failing a TKI, we 
hypothesized that substitutions in any of these residues might alter protein stability. To address this issue, we 
initially employed the above-indicated ABL constructs that were lentivirally transduced in the Ba/F3 cell line. 
We found that all ABL mutants were expressed at levels comparable to the wild-type protein and were devoid 
of catalytic activity (Fig. 2A) and transforming potential (Fig. 2B). Expectedly, the ABLT315I control represented 
the only exception to these findings as this protein showed high kinase proficiency thereby allowing Ba/F3 
proliferation and survival in the absence of IL-3 (54) (Fig. 2A, B). 
Since wild-type ABL displays very low tyrosine phosphorylation, we could not investigate the influence of each 
substitution in modulating catalytic activity. We therefore repeated the same experiments employing the 
corresponding BCR-ABL constructs, exploiting the oncoprotein’s constitutive kinase activity (2). While again 
all mutants were expressed at levels comparable to those of BCR-ABLWT, any substitution involving residues 
E286, M318 and D381 completely abrogated their kinase proficiency. The conservative I360T substitution was 
the only tested variation capable of maintaining BCR-ABL tyrosine phosphorylation (Fig. 2C). Accordingly, 
only Ba/F3 cells expressing BCR-ABLI360T survived and proliferated after IL-3 withdrawal, albeit at lower 
levels than those reported for BCR-ABLWT and BCR-ABLT315I (Fig. 2D). 
To further confirm these results we also performed an in vitro kinase assay using purified BCR-ABL mutants 
and a previously reported synthetic peptide substrate (55). The Michaelis-Menten parameters describing 
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substrate binding (Km), maximum rate (Vmax) and catalytic constant rate (Kcat) were determined using nonlinear 
regression fits. A KI BCR-ABL was included in the experiments as a negative control (34). As expected, seven 
of eight BCR-ABL mutants generated Vmax values similar to the KI protein, indicating complete lack of 
phosphorylation of the synthetic substrate (Fig. 2E, F). On the contrary, BCR-ABLI360T maintained its kinase 
activity, although at lower levels than BCR-ABLWT. However, the low Km value displayed by this mutant 
suggests that minimal substrate concentrations are sufficient to saturate its catalytic activity (Fig. 2F). 
We complemented the experimental validation with an in silico screening of the expected effects of mutations 
on these positions (Table 2). Three sequence-based methods (PROVEAN, SIFT, polyphen-2) consistently 
predicted the majority of the substitutions as deleterious (labeled ‘Not Tolerated’ in SIFT or ‘damaging’ in 
polyphen-2). A few cases were predicted as deleterious by two of three methods and only selected substitutions 
in I360 were suggested as possibly tolerated. Sequence-based methods predict the expected effect on both 
stability and function. To isolate the contribution from protein structure destabilization we performed an 
analysis of the mutants using MOE. The difference in free energy of folding (⊗⊗G) of the mutants versus the 
wild-type are also reported in Table 2. Substitutions on position M318 and I360 are generally destabilizing 
(⊗⊗G > 1 kcal/mol in bold in Table 2), whereas changes on E286 and D381 do not impact stability, suggesting 
that they are deleterious for their effect on function. 
Overall, these results offer a solid rationale for the observed lack of mutations on residues E286, M318 and 
D381 in CML patients failing TKI treatment. Indeed, both conservative and non-conservative substitutions of 
these amino acids would result in loss of BCR-ABL catalytic activity, thus compromising its transforming 
potential. In contrast, a conservative substitution in position 360 appeared to preserve BCR-ABL kinase 
functionality. 
 
Molecular Dynamics simulations of BCR-ABL mutants I360T and I360R reveal differences in the helix- 
αC dynamics and in the protein correlated motions 
In an effort to better understand the structural and dynamical differences between the KDs of the kinase-
proficient I360T and the kinase-deficient I360R, we analyzed the MD trajectories of both BCR-ABL mutants 
and compared them to the wild-type oncoprotein. In particular, we investigated the correlation between the 
motions of the different parts of the protein. This was then mapped onto the protein structures using correlation 
webs, where residues that move together are connected by a line (Fig 3A, B, C top panels). Correlated motions 
were previously shown to be critical for the activation of the ABL TK domain (26). 
We found that the correlated motions of the BCR-ABLI360T KD were mostly located at the bottom of the 
catalytic pocket. On the contrary the N-terminal of helix-αC is not coupled in its motion to the N-lobe as in the 
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wild-type domain. This provides more freedom of motion to helix-αC that shifts upward and towards the 
outside (Fig. 3A, B, top panels). We then analyzed the conformational changes and stability of helix-αC by 
plotting its time evolution along the sequence. We observed that, in BCR-ABLI360T, helix-αC maintained its 
structure despite retaining the modified orientation for the rest of the simulated time (Fig. 3B, bottom panel, red 
arrow). BCR-ABLI360R presented a strong decrease in correlated motions compared to both the wild-type 
oncoprotein and the I360T variant (Fig. 3C, top panel). The I360R mutant also showed an upward shift of helix-
αC that appeared to partially unwind for a 6 ns interval in the middle of the simulation (Fig. 3C, bottom panel, 
red arrow). 
Overall, our results detected differences in the dynamics of BCR-ABLI360T and BCR-ABLI360R that could be 
related to the diverse catalytic activity of these mutants. However, it remained to be established if different 
TKIs would successfully abrogate the catalytic activity of BCR-ABLI360T. 
 
The persistence of some hydrogen bond interactions is critical for successful inhibition of BCR-ABLI360T 
kinase activity by TKIs 
To investigate whether PON would suppress BCR-ABLI360T kinase activity we simulated this mutant’s KD in 
complex with the drug, and analyzed the average distance of the residues involved in hydrogen bond 
interactions during the simulations. Since BCR-ABLI360T has never been reported in the literature, we also 
analyzed this mutant in complex with IM and DAS. Additional simulations were performed with the KDs of 
BCR-ABLWT and BCR-ABLT315I used as controls. The time evolution of the Root Mean Square Deviation on 
the Cα atoms indicated that all systems rapidly reached equilibrium and remained stable during the simulated 
time (Supplemental Fig. S1). 
PON binds the inactive conformation of the BCR-ABLWT kinase establishing four hydrogen bonds with E286, 
M318, I360 and D381 (31) (Fig. 4A). These interactions remained stable during the simulation with the 
exception of the transient binding with E286 (Fig. 4A). Since PON does not form hydrogen bonds with 
Threonine 315, its mutation to Isoleucine should not affect drug binding (56). Indeed, in our BCR-ABLT315I-
PON system, the drug maintained persistent interactions with M318, I360 and D381, while again binding to 
E286 was transient (Fig. 4B). Moreover, PON’s linear ethynyl linker helped the compound to skirt the steric 
hindrance phenomenon caused by I315. In the BCR-ABLI360T-PON system, loss of the hydrogen bond with 
I360 coupled with the weak interaction with E286 did not affect the drug’s ability to bind this mutant (Fig. 4C). 
Hence, our simulations suggested that PON should effectively suppress the catalytic activity of the I360T 
mutant. 
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Like PON, IM binds the BCR-ABL KD in the inactive conformation generating hydrogen bond interactions 
with the four residues described above (E286, M318, I360, D381) plus the gatekeeper Threonine in position 315 
(32, 57) (Fig. 4D). Our analysis showed that these interactions persisted during the entire BCR-ABLWT 
simulation, with small oscillations of the drug’s tail that caused one short increase of the distance from I360 in 
the middle of the simulated time (Fig. 4D). In the BCR-ABLT315I-IM system, the drug adapted to the 
mutagenized catalytic pocket thanks to a slightly outward displacement, thus avoiding the increased steric 
hindrance caused by the Isoleucine side-chain. These changes can be appreciated by comparing the differences 
in IM structure depicted in Fig. 4D, E. This spatial rearrangement alleviated the clash of bulky residues. 
However, in the simulation, the drug lost three of five hydrogen bond interactions compromising optimal 
protein binding. Indeed, aside from the loss of the hydrogen bond with Threonine 315 because of its substitution 
with Isoleucine, we observed displacements of the interactions with E286 and I360 (Fig. 4E). Analysis of BCR-
ABLI360T in complex with IM revealed that all hydrogen bond interactions previously shown for the wild-type 
system were maintained over time, with the exception of the interaction with the mutagenized I360 residue. 
Insertion of a Threonine at this site caused a slight change in the conformation of the activation loop resulting in 
a missing hydrogen bond with the tail of the drug (Fig. 4F). However, IM binding appeared stable despite this 
alteration. 
Unlike PON, DAS binds the BCR-ABL catalytic pocket in the active conformation forming three hydrogen 
bond interactions: one with T315 and two with M318 (33) (Fig. 4G). Hydrogen bonds analysis of BCR-ABLWT 
in complex with DAS showed that these three points of contact were preserved over the entire simulation (Fig. 
4G). Both biological and clinical evidences have demonstrated that DAS is unable to inhibit the T315I 
gatekeeper mutation (58, 59). Simulation of BCR-ABLT315I in complex with DAS showed the expected loss of 
the critical interaction with I315 (33) (Fig. 4H). In this case the hydrophobic pocket of the BCR-ABL KD plays 
a key role in anchoring the phenyl ring of DAS through hydrophobic interactions with several amino acids. Four 
residues (M290, V299, I313 and F382) all located in this region (33), showed an increased distance from the 
inhibitor in the BCR-ABLT315I-DAS system, becoming unavailable for hydrophobic interactions (Supplemental 
Fig. S2). Thus, the loss of DAS binding to BCR-ABLT315I can mainly be attributed to changes in the 
hydrophobic anchoring of the drug. However, DAS did not lose any hydrogen bond interactions with BCR-
ABLI360T, implying effectiveness of this drug in inhibiting the kinase activity of the I360T mutant (Fig. 4I). 
In addition to the MD simulations, we also estimated the free energy of binding (⊗G) for each of the TKIs with 
the simulated systems. The ⊗G values were calculated with MOE and are reported in Table 3, together with 
their corresponding pKi values. Results are generally consistent with our simulations: PON shows effective 
binding in all three systems, DAS has a decreased ability to bind BCR-ABLT315I, while IM maintains a strong 
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binding to BCR-ABLI360T. The apparent inconsistency of the values for IM:T315I and I360T:DAS can be 
explained considering that the approximate free energy calculation included in MOE cannot accurately describe 
contributions from significant conformational changes in the oncoprotein. From previous studies (54) we know 
that this is the case for the destabilization of the interaction of the gatekeeper mutant with IM. It is possible that 
conformational changes also play a role in modulating DAS binding affinity for the previously uncharacterized 
I360T mutant. 
In summary, our computational analyses suggest that BCR-ABLI360T should be responsive to PON, IM and 
DAS. 
 
Ponatinib, Imatinib and Dasatinib inhibit BCR-ABLI360T kinase activity suppressing its transforming 
potential 
To ascertain the validity of our computational analysis on BCR-ABLI360T we initially exposed Ba/F3 cells 
expressing this construct to increasing concentrations of PON, IM and DAS after IL-3 deprivation. Calculation 
of the IC50 values for cellular proliferation in response to each TKI confirmed our computational predictions, as 
the I360T mutant was sensitive to each drug displaying inferior IC50 rates than the wild-type oncoprotein (Fig. 
6A, B and C, left panels, Fig. 6D). We next analyzed total tyrosine phosphorylation levels after a 24 hour 
exposure to the three inhibitors and found that BCR-ABLI360T catalytic activity was efficiently suppressed by 
each TKI (Fig. 5A, B and C, right panels). Finally, our experiments also confirmed that PON was the only 
effective compound for the treatment of BCR-ABLT315I (Fig. 5A), whereas the wild-type oncoprotein was 
responsive to all TKIs. 
Thus, PON, IM and DAS all successfully inhibited BCR-ABLI360T oncogenic activity, as predicted by the 
hydrogen bond interactions analysis (Fig. 4). These data also explain why the I360T substitution has never been 
observed in CML patients unresponsive to TKIs as, in spite of the transforming potential of this mutant, BCR-
ABLI360T remains sensitive to multiple kinase inhibitors. 
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DISCUSSION 
 
Over 100 point mutations involving more than 60 amino acidic residues have been associated with TKI 
resistance in CML patients (12-15). However, no study has ever reported amino acidic substitutions involving 
E286, M318, I360 and D381, four residues of the BCR-ABL kinase that generate hydrogen bond interactions 
with PON (31). In this manuscript we present biological and computational data demonstrating that these four 
amino acids play a pivotal role in preserving BCR-ABL transforming activity. Indeed, our results suggest that - 
with the exception of the I360T substitution - both conservative and non-conservative mutations in E286, 
M318, I360 and D381 abolish BCR-ABL kinase activity. These findings explain the lack of point mutations in 
these four amino acidic residues, as any change in these sites would be selected against by either lack of 
catalytic activity or maintained responsiveness to TKI treatment, as we observed with BCR-ABLI360T. These 
findings are also corroborated by sequencing data derived from 95 CML patients that either failed IM or 
achieved suboptimal responses according to the 2009 European Leukemia Net criteria (60). In these analyses 
we detected the E286K mutation in one subject, three substitutions at the M318 residue (M318T-V-I) in three 
patients, and three amino acidic replacements at the I360 residue (I360T-L-S) in five further patients. All 
substitutions were found in a small percentage of clones (<10%) and none were detected when sequencing the 
same patients at a later time (Stella S and Vigneri P, unpublished data). 
 
Since the I360T mutation preserved BCR-ABL catalytic activity, we investigated this amino acidic substitution 
from a computational standpoint, comparing it to the corresponding non-conservative I360R mutation devoid of 
kinase activity. MD simulations of these two mutants revealed major differences in correlated motions and in 
the dynamics of helix-αC as compared to wild-type BCR-ABL. I360T displayed strong correlations in the 
region between the N- and C-lobes of the BCR-ABL catalytic region. We also detected a significant upward 
shift of helix-αC, which is allowed more freedom and is partially displaced from the core of the domain, with an 
ensuing tendency in widening the access to the binding cavity. These results suggest a modified arrangement of 
the ATP pocket that could compromise ATP binding and would be compatible with the reduced kinase activity 
of this mutant. More dramatic changes were detected in the dynamics of helix-αC in BCR-ABLI360R as in this 
mutant the helix is looser and has a tendency to unwind. In addition, the domain has lost the inter-lobe 
communication known to be critical for activation (26). This is in line with the drastic reduction of kinase 
activity observed for this mutant. In addition, hydrogen bond interaction analyses followed by biochemical and 
survival assays demonstrated that PON, IM and DAS successfully inhibit BCR-ABLI360T. 
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Hydrogen bond analyses also contributed to explain the structural reasons underlying the resistance of the 
T315I gatekeeper mutation to IM and DAS. The common hypotheses advocated to explain IM and DAS failure 
in suppressing BCR-ABLT315I is that this substitution mediates drug resistance through a steric hindrance 
mechanism (61). However, by studying the dynamics of the inhibitor bound systems in-silico, we found that a 
slightly outward displacement of both IM and DAS allowed these drugs to adapt to the T315I catalytic pocket, 
thus circumventing the increased steric hindrance caused by the bulky Isoleucine side-chain (Fig. 4D, E). 
Indeed, the steric hindrance generated by the T315I mutation does not lead to complete obstruction of the 
binding cavity and the flexibility of the drug structure allows for a suitable rearrangement around the bulkier 
side-chain, unlike cases in which more rigid molecules cannot fit into partially (or totally) occluded pockets. 
This is generally not visible from a single experimental structure, but requires the simulation of the system to 
estimate the degree of flexibility of both drug and protein. We therefore investigated other mechanisms 
contributing to the lack of efficacy of IM and DAS on BCR-ABLT315I. In accordance with previous reports, we 
found that loss of hydrogen bonds between IM and E286, T315 (replaced by an Isoleucine) and I360 in the 
BCR-ABLT315I KD played a pivotal role in IM failure against the T315I mutation (30). However, loss of 
hydrogen bonds was not sufficient to explain BCR-ABLT315I resistance to DAS as only the interaction between 
T315 and DAS was compromised in the T315I mutant simulations. Upon further investigation we detected a 
perturbation in the dynamics of amino acidic residues that form hydrophobic interactions with the drug. These 
alterations are likely to factor heavily in the lack of DAS binding to the T315I mutant. 
 
Further computational investigations of BCR-ABLT315I revealed a net enhancement of correlated motions within 
the N- and C-lobes as compared to the wild-type oncoprotein (Fig. 6A, B). The mutation affects the dynamics of 
the two lobes modifying the access to and the shape of the binding site. The correlations also involve helix-αC 
(which undergoes a partial unwinding) and the activation loop, suggesting that the T315I mutation dynamically 
perturbs several structural elements crucially involved in drug binding (Fig. 6B). This observation is in line with 
previous suggestions about the main role of gatekeeper mutations in orchestrating an effective communication 
between the two lobes (26) and in stabilizing the hydrophobic spine (17, 54). Simulation of the BCR-ABLT315I-
PON system showed that, aside from the effects ascribed to the ethynyl linker in bypassing the steric hindrance 
(31), three pivotal features enabled this drug to inhibit BCR-ABLT315I: i) as in the wild-type domain, PON 
showed intermittent interactions with E286, which is often dislocated from its natural position when helix-αC is 
destabilized; ii) the drug maintained the same hydrogen bond interactions and the same average distance with 
all residues involved in hydrophobic contacts in the BCR-ABLWT-PON simulation; iii) there were only minor 
differences between the BCR-ABLWT-PON and BCR-ABLT315I-PON systems in terms of correlated motions 
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(Fig. 6C, D), implying that PON seems to “revert” the dynamics of the T315I mutant to those of BCR-ABL 
wild-type. 
 
The critical issue stemming from our results concerns the implications of the reported findings for future 
therapeutic developments. CML patients unresponsive to TKI treatment sometimes develop point mutations 
involving multiple residues within the BCR-ABL KD (12-15, 62). It should be emphasized that amino acidic 
substitutions engaging different residues of a catalytic domain are not a prerogative of the ABL kinase, as 
identical phenomena (including mutations of the gatekeeper Threonine) have been reported in patients 
diagnosed with lung cancer or gastro-intestinal tumors failing Epidermal Growth Factor Receptor or c-KIT 
inhibitors, respectively (63, 64). Two different approaches have been pursued to address these problems. 
Several companies have synthesized irreversible TKIs that, unlike reversible inhibitors (e.g. IM), generate 
covalent bonds with specific amino acidic residues (usually Cysteines but also Serines, Threonines or Lysines) 
of their substrate(s). While highly effective, irreversible TKIs have often been associated with increased 
(sometimes limiting) toxicities that have hindered their clinical development (65). An alternative approach has 
been to design compounds that do not interact with the critical gatekeeper residue of the substrate kinase (66). 
The caveat of this method is that - theoretically - amino acidic substitutions in residues other than the 
gatekeeper could induce resistance to these drugs. However, to date, no single point mutations have been 
associated with resistance to PON. Our data suggest that the lack of mutations causing PON failure derives from 
the fact that this inhibitor forms hydrogen bonds with four critical residues (E286, M318, I360 and D381) of the 
BCR-ABL KD that, if mutated, would compromise the transforming ability of the oncoprotein. Hence, changes 
in any of the above-mentioned four residues would be selected against by a lack of kinase activity or by 
maintained responsiveness to TKIs (BCR-ABLI360T). Interestingly, when we analyzed the twelve known PON 
biological targets (9, 67), we found that these tyrosine kinases conserved the ABL E, I/V and D residues but 
displayed different substitutions in place of M318 (Fig. 7A). These results suggest a structural scenario in which 
E286, M318, I360 and D381 are “untouchable” residues for the ABL kinase, but only E, I and D are critical for 
the remaining PON targets as the Methionine in position 318 can be replaced by either an Alanine or a Cysteine. 
 
Remarkably, residues equivalent to ABL E286, M318, I360 and D381 are conserved in 46 of 90 (51%) human 
tyrosine kinases including both receptor and non-receptor proteins (Fig. 7B). Forty-two of these 46 tyrosine 
kinases were tested for PON responsiveness in a previously published in vitro kinase assay and 25 of 42 (59%) 
were efficiently inhibited by the drug (IC50 <20 nM) (9). While we can’t offer a detailed explanation as to why 
PON lacks efficacy on the remaining 17 kinases, several observations should be kept in mind. Specifically: i) 
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while a sequence alignment suggests that E, M, I and D residues are preserved in these TKs, a large-scale 
Molecular Dynamics study would be necessary to confirm that these amino acids conserve a similar role in 
protein flexibility compared to the ABL KD, in line with recent evidence that selective inhibition of TKs could 
also be connected to differences in their intrinsic dynamics (19, 22); ii) since our current structural information 
is mostly limited to the catalytic domain of multiple tyrosine kinases, we can not account for the significant 
modifications that other portions of the protein may exert on the catalytic pocket, heavily affecting PON 
binding; iii) likewise, the shape and orientation of the drug binding pocket of each TK may present subtle 
differences that could partially or completely abrogate its interaction with PON. Hence, preservation of E, M, I 
and D residues in positions equivalent to those of the ABL KD appears to be necessary but not sufficient to 
predict PON binding to other TKs. 
 
In summary, we report here the identification of four amino acidic residues (E286, M318, I360 and D381) that 
are critical for BCR-ABL catalytic activity and leukemogenic potential. We also find that these amino acids are 
conserved in several human tyrosine kinases and are likely to represent unmodifiable residues that contribute to 
the proper structural folding and enzymatic activity of these proteins. Small molecule inhibitors targeting these 
amino acids in other tyrosine kinases might be of great clinical interest to avoid the emergence of resistance due 
to point mutations. 
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FIGURE LEGENDS 
 
Figure 1. Cartoon showing the amino acids within the BCR-ABL catalytic domain that generate hydrogen 
bonds with different TKIs. Structural representation of PON (brown; PDB accession number: 3OXZ) (A), IM 
(orange; PDB accession number: 2HYY) (B) and DAS (blue; PDB accession number: 2GQG) (C) fitted inside 
the BCR-ABL KD (top panels). In lower panels, amino acidic residues generating hydrogen bonds with each 
drug are highlighted with the corresponding color. 
 
Figure 2. I360T is the only substitution that maintains BCR-ABL catalytic activity and transforming potential. 
A) Cell lysates from Ba/F3 cells lentivirally transduced with HA-tagged ABL constructs displaying the specified 
mutations were blotted using anti-HA (top panel), anti-phosphotyrosine (middle panel) or anti-Actin (bottom 
panel) antibodies. Wild-type (WT) and T315I constructs were used as controls. EV = empty vector. Actin levels 
confirmed equal protein loading in each lane. B) The same cells were also employed to perform proliferation 
assays for 24, 48 or 72 hours. Numbers represent average ± standard deviations of three separate experiments 
performed in quadruplicates. Results are expressed as relative luminescence fold increase with cells plated at 
baseline arbitrarily set at 1. C, D) Identical experiments were repeated on Ba/F3 cells transduced with FLAG-
tagged BCR-ABL mutants that reproduce the amino acidic substitutions generated for ABL. Anti-FLAG 
immunoblots confirmed protein expression of each construct. E) In vitro kinase reactions of BCR-ABL mutants 
were performed in the presence of increasing concentrations of the Abltide synthetic substrate. Velocity is 
plotted versus peptide concentrations in a Michaelis-Menten graph. KI BCR-ABL was used as negative control. 
Velocity values are expressed as relative luminescence fold increase, with background calculated by omitting 
substrate addition in the reaction. Results shown represent average ± standard deviations of three separate 
experiments performed in triplicates. F) Km and Vmax values of different BCR-ABL mutants obtained from the 
Michaelis-Menten equation by plotting the velocity of the reactions as a function of the substrate concentration. 
Kcat values were generated from the equation kcat = Vmax/[enzyme]. 
 
Figure 3. I360T and I360R kinase domains display differences in correlated motions and helix-αC dynamics 
compared to ABL wild-type. Correlation webs calculated from 50 ns production runs for ABLWT (A), ABLI360T 
(B) and ABLI360R (C) KDs are shown as a cartoon representation with the DFG motif indicated in red and the 
activation loop in blue. Residues with correlated motions are connected by a line. Only correlations greater than 
0.6 were reported. The time evolution of the secondary structure elements during the molecular dynamics 
simulations is shown below each cartoon. The simulation time is reported on the x-axis while the protein 
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residues index is specified on the y-axis. Residues belonging to helix-αC are designated by a red arrow. 
Secondary structures were attributed with DSSP (45): α-helixes (blue), β-sheets (red), turns (yellow), bends 
(green), B-bridges (black), coils (white), 3-helixes (gray). 
 
Figure 4. Variations in hydrogen bond interactions modulate TKI efficacy on BCR-ABLI360T. Average 
distances of hydrogen bond interactions between PON (A, B, C), IM (D, E, F) or DAS (G, H, I) and the 
indicated residues. Results were computed for BCR-ABLWT and for the T315I and I360T mutants. Top panels 
show time evolution of the distances between inhibitors and residues. Lines were colored according to the tint 
of each amino acid (blue E286, orange T315, black M318, green I360 and red D381). Bottom panels are a 
snapshot collected after 35 ns of the corresponding simulation, with inhibitor structure shown in liquorice and 
weak (>3.5 Å, red) or strong (<3.5 Å, blue) hydrogen bonds represented as dashed lines. 
 
Figure 5. BCR-ABLI360T catalytic activity is suppressed by multiple TKIs. A, B, C) To calculate IC50 values for 
the specified TKIs, Ba/F3 cells transduced with empty vector (EV) (!), BCR-ABLWT (!), BCR-ABLT315I (!) or 
BCR-ABLI360T (") were treated for 24 hours with increasing concentrations of PON, IM or DAS. Values shown 
are expressed as fold decrease, with untreated cells arbitrarily set at 100 (left panels). To verify BCR-ABL 
inhibition, cell lysates from Ba/F3 cells expressing the indicated mutants were blotted using an anti-
phosphotyrosine (p-Tyr) antibody (right panels). D) Average IC50 values derived from three independent 
experiments performed in triplicates. 
 
Figure 6. Ponatinib “reverts” the dynamics of the BCR-ABLT315I catalytic domain to those of the wild-type 
oncoprotein. Correlation webs were calculated over 50 ns production runs and reported on the cartoon 
representation of BCR-ABLWT (A) and BCR-ABLT315I (B), alone or complexed (C, D) with PON. Only 
correlations greater than 0.6 were included. 
 
Figure 7. BCR-ABL amino acidic residues E286, M318, I360 and D381 are conserved in multiple human 
tyrosine kinases. A) Table including the twelve known PON targets, that summarizes the position of the 
conserved residues in the specified protein kinases. An Alanine or a Cysteine are always found in place of 
BCR-ABL M318. Isoleucine is replaced by a Valine in 4 of 12 proteins. This conservative substitution does not 
influence the interaction with the inhibitor, since the hydrogen bond generated with PON involves the backbone 
oxygen of I360 and can be reproduced by the equivalent oxygen atom in the Valine backbone. B) List of 46 
human tyrosine kinases displaying residues equivalent to E286, M318, I360 and D381 identified in the BCR-
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ABL KD. Isoleucine in position 360 is replaced by a Valine in 29 of 46 tyrosine kinases. The reported proteins 
were efficiently inhibited by PON (IC50 <20nM) in a previously published in vitro kinase assay, with the 
exception of the underlined kinases (IC50 >20nM). Proteins in italics have not been tested. 
Table 1. Conservative (C) and non-conservative (NC) substitutions inserted in the BCR-ABL catalytic domain 
 
AMINO ACID ABL POSITION (C) MUTATION (NC) MUTATION 
Glutamic Acid (E) 286 Aspartic Acid (D) Arginine (R) 
Methionine (M) 318 Threonine (T) Lysine (K) 
Isoleucine (I) 360 Threonine (T) Arginine (R) 
Aspartic Acid (D) 381 Glutamic Acid (E) Arginine (R) 
 
Letters in parenthesis refer to the corresponding single letter code for each amino acidic residue. Amino acid 
positions specified above are derived from the human ABL1A protein sequence (NCBI accession number 
NP_005148.2). However, in the manuscript we attribute these residues to the BCR-ABL sequence maintaining 
the ABL numbering. 
Table 2. In silico prediction of the effects of different mutations on amino acid positions 286, 318, 360 and 381 
  PROVEAN SIFT polyphen-2 MOE ΔΔG (kcal/mol) 
E286A Deleterious Not Tolerated damaging -2.49 
E286C Deleterious Not Tolerated damaging -5.72 
E286D Deleterious Not Tolerated damaging -1.90 
E286F Deleterious Not Tolerated damaging -3.55 
E286G Deleterious Not Tolerated damaging -1.39 
E286H Deleterious Not Tolerated damaging -0.62 
E286I Deleterious Not Tolerated damaging -3.73 
E286K Deleterious Not Tolerated damaging 1.13 
E286L Deleterious Not Tolerated damaging -4.52 
E286M Deleterious Not Tolerated damaging -4.19 
E286N Deleterious Not Tolerated damaging -2.47 
E286P Deleterious Not Tolerated damaging -2.65 
E286Q Deleterious Not Tolerated damaging -1.88 
E286R Deleterious Not Tolerated damaging -3.40 
E286S Deleterious Not Tolerated damaging -3.00 
E286T Deleterious Not Tolerated possibly damaging -2.40 
E286V Deleterious Not Tolerated damaging -3.93 
E286W Deleterious Not Tolerated damaging -2.64 
E286Y Deleterious Not Tolerated damaging -5.21 
     
M318A Deleterious Not Tolerated damaging 1.26 
M318C Deleterious Not Tolerated damaging -1.45 
M318D Deleterious Not Tolerated damaging 4.73 
M318E Deleterious Not Tolerated damaging 5.55 
M318F Deleterious Not Tolerated damaging 4.01 
M318G Deleterious Not Tolerated damaging 3.90 
M318H Deleterious Not Tolerated damaging 9.37 
M318I Deleterious Not Tolerated damaging -0.26 
M318K Deleterious Not Tolerated damaging 2.79 
M318L Deleterious Not Tolerated possibly damaging -0.01 
M318N Deleterious Not Tolerated damaging 1.38 
M318P Deleterious Not Tolerated damaging -0.92 
M318Q Deleterious Not Tolerated damaging 3.55 
M318R Deleterious Not Tolerated damaging 7.68 
M318S Deleterious Not Tolerated damaging 2.31 
M318T Deleterious Not Tolerated damaging 1.88 
M318V Deleterious Not Tolerated possibly damaging -0.09 
M318W Deleterious Not Tolerated damaging 5.32 
M318Y Deleterious Not Tolerated damaging 2.96 
     
I360A Deleterious Not Tolerated damaging 0.50 
I360C Deleterious Not Tolerated damaging -1.60 
I360D Deleterious Not Tolerated damaging 3.05 
I360E Deleterious Not Tolerated damaging 1.85 
I360F Deleterious Not Tolerated damaging 1.18 
I360G Deleterious Not Tolerated damaging 2.71 
I360H Deleterious Not Tolerated damaging 3.30 
I360K Deleterious Not Tolerated damaging 1.49 
I360L Neutral Not Tolerated possibly damaging -0.03 
I360M Deleterious Not Tolerated damaging 0.38 
I360N Deleterious Not Tolerated damaging 1.13 
I360P Deleterious Not Tolerated damaging -0.38 
I360Q Deleterious Not Tolerated damaging 2.00 
I360R Deleterious Not Tolerated damaging 1.83 
I360S Deleterious Not Tolerated damaging 0.76 
I360T Deleterious Not Tolerated damaging 1.65 
I360V Neutral Tolerated possibly damaging -0.10 
I360W Deleterious Not Tolerated damaging 1.51 
I360Y Deleterious Not Tolerated damaging -0.26 
     
D381A Deleterious Not Tolerated damaging -2.34 
D381C Deleterious Not Tolerated damaging -4.91 
D381E Deleterious Not Tolerated damaging -0.36 
D381F Deleterious Not Tolerated damaging -5.21 
D381G Deleterious Not Tolerated damaging -1.47 
D381H Deleterious Not Tolerated damaging -1.51 
D381I Deleterious Not Tolerated damaging -4.73 
D381K Deleterious Not Tolerated damaging 0.91 
D381L Deleterious Not Tolerated damaging -4.72 
D381M Deleterious Not Tolerated damaging -4.16 
D381N Deleterious Not Tolerated damaging -2.58 
D381P Deleterious Not Tolerated damaging -6.07 
D381Q Deleterious Not Tolerated damaging -2.33 
D381R Deleterious Not Tolerated damaging -1.69 
D381S Deleterious Not Tolerated damaging -3.11 
D381T Deleterious Not Tolerated damaging -2.68 
D381V Deleterious Not Tolerated damaging -4.50 
D381W Deleterious Not Tolerated damaging -3.26 
D381Y Deleterious Not Tolerated damaging -4.66 
 
  
Table 3. Binding free energies and inhibition constants for the different TKIs bound to the simulated mutants 
 ΔG (kcal/mol) pKi 
  PON IM DAS PON IM DAS 
WT -13.8 -13.5 -12.5 10.0 9.8 9.1 
T315I -13.4 -14.0 -10.0 9.8 10.2 7.3 
I360T -13.1 -16.0 -10.6 9.5 11.7 7.7 
 
 
pKi are calculated as -log Kd, where Kd is the dissociation constant derived from the corresponding ΔG of 
binding. 
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A      B     
           
  E M I/V D    E M I/V D 
ABL 286 318 I 360 381  ABL 286 318 I 360 381 
FGFR1 531 A 564 I 620 641  ALK 1167 1199 I 1246 1270 
FGFR2 534 A 567 I 623 644  ARG 332 364 I 406 427 
FGFR3 525 A 558 I 614 635  BLK 284 315 I 357 378 
FGFR4 520 A 553 I 609 630  BRK 235 267 I 309 330 
FLT3 661 C 694 V 808 829  CSK 236 269 V 311 332 
KIT 640 C 673 I 789 810  DDR1 672 704 V 763 784 
PDGFRa 644 C 677 V 815 836  DDR2 625 657 V 707 728 
PDGFRb 651 C 684 V 823 844  EGFR 762 793 V 834 855 
RET 775 A 807 V 871 892  EphA1 673 705 V 746 767 
VEGFR1 878 C 912 I 1019 1040  EphA2 663 695 V 736 757 
VEGFR2 885 C 919 I 1025 1046  EphA3 670 702 V 743 764 
VEGFR3 896 C 930 I 1034 1055  EphA4 670 702 V 743 764 
      EphA5 724 756 V 797 818 
      EphA6 679 753 V 794 815 
      EphA7 682 714 V 755 776 
      EphA8 684 716 V 757 778 
      EphB1 668 700 V 741 762 
      EphB2 670 702 V 743 764 
      EphB3 682 714 V 755 776 
      EphB4 664 696 V 737 758 
      ErbB2 770 801 V 842 863 
      ErbB4 768 799 V 840 861 
      FGR 306 337 I 379 400 
      FRK 277 309 I 351 372 
      FYN 314 345 I 387 408 
      HCK 305 336 I 378 399 
      IGF1R 1050 1082 V 1132 1153 
      INSR 1074 1106 V 1156 1176 
      IRR 1030 1062 V 1112 1133 
      ITK 406 438 I 479 500 
      LCK 288 319 I 361 382 
      LTK 561 593 I 640 664 
      LYN 290 322 I 364 385 
      MET 1127 1160 V 1201 1222 
      MUSK 626 658 V 722 743 
      RON 1131 1164 V 1205 1226 
      ROS 1997 2029 I 2076 2102 
      SRC 312 343 V 385 406 
      TEC 413 445 I 486 507 
      TRKA 560 592 V 647 668 
      TRKB 588 620 V 673 694 
      TRKC 588 620 V 673 694 
      TXK 314 346 I 387 408 
      TYR03 568 606 I 652 673 
      YES 320 351 I 393 414 
      Zap70 386 416 V 458 479 
 
